共 78 条
[1]
Balogh J(2016)Hepatocellular carcinoma: a review J Hepatocell Carcinoma. 3 41-53
[2]
Victor D(2013)Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia–Pacific region J Gastroenterol 48 681-688
[3]
Asham EH(1996)Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis J Gastroenterol 31 552-558
[4]
Kim MN(1993)A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis Hepatology 18 47-53
[5]
Kim BK(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390
[6]
Han K-H(2009)Efficacy and safety of sorafenib in patients in the Asia–Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol. 10 25-34
[7]
Chiba T(2013)Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial J Clin Oncol 31 4067-4075
[8]
Matsuzaki Y(2013)Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study J Clin Oncol 31 3517-3524
[9]
Abei M(2015)Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial J Clin Oncol 33 172-179
[10]
Ikeda K(2015)SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma J Clin Oncol 33 559-566